Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.59 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2825118 | 0.84 | CYP2A6 (0.61) | CYP2A6IMPDH2PBRM1HPGDHTT | |
| SCHEMBL3193704 | 0.83 | MAPT (0.68) | CYP2A6IMPDH2PBRM1HPGDHTT | |
| SCHEMBL3193708 | 0.83 | MAPT (0.68) | CYP2A6IMPDH2PBRM1HPGDHTT | |
| 3-Formylindole SCHEMBL28119225 | 0.81 | CYP2A6 (0.79) | CYP2A6IMPDH2PBRM1HPGDHTT | |
| SCHEMBL15487095 | 0.78 | CYP2A6 (0.54) | CYP2A6IMPDH2PBRM1HPGDHTT | |
| SCHEMBL9347052 | 0.78 | CYP2A6 (0.54) | CYP2A6IMPDH2HPGDHTTKMT2A | |
| SCHEMBL7594725 | 0.78 | CYP2A6 (0.54) | CYP2A6IMPDH2PBRM1HPGDHTT | |
| SCHEMBL15487094 | 0.78 | CYP2A6 (0.54) | CYP2A6IMPDH2PBRM1HPGDHTT | |
| SCHEMBL13811016 | 0.78 | APP (0.62) | CYP2A6IMPDH2PBRM1HPGDHTT | |
| SCHEMBL8574534 | 0.78 | KMT2A (0.64) | CYP2A6IMPDH2PBRM1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616442-B1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS INC (US) | 2018-08-08 | — | — | EP | claimed |
| US-9670212-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2017-06-06 | — | — | US | claimed |
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | claimed |
| US-20140303151-A9 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-10-09 | — | — | US | claimed |
| US-20140045825-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-13 | — | — | US | claimed |
| JP-4641942-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| US-20240115626-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-11801273-B2 | Compositions and methods to increase production of isothiocyanates | CHURCH & DWIGHT CO., INC. (US) | 2023-10-31 | — | — | US | disclosed |
| WO-2022140409-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220193152-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION OF ISOTHIOCYANATES | CHURCH & DWIGHT CO., INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-10716778-B2 | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals | Veijlen (CW) | 2020-07-21 | — | — | US | disclosed |
| US-10053470-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20070184091-A1 | Animal feed composition | VEIJLEN N.V. (AN) | 2007-08-09 | — | — | US | disclosed |
| WO-2007085660-A1 | PESTICIDAL COMPOSITION COMPRISING INDOLE DERIVATES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2007-08-02 | — | — | WO | disclosed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | disclosed |
| EP-1667678-A1 | ANIMAL FEED COMPOSITION | Veijlen N.V. (AN) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005034942-A1 | ANIMAL FEED COMPOSITION | VEIJLEN N.V. (AN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303151-A9 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | CYP2A6 1509/4885IMPDH2 1813/4885PBRM1 2269/4885 |
| US-10053470-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | PIK3CD, PIK3CA, PIK3R5 | CYP2A6 1417/4885IMPDH2 1809/4885PBRM1 2261/4885 |
| US-20140045825-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | CYP2A6 1509/4885IMPDH2 1813/4885PBRM1 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.